Michelle Hoffman
This is the bio for Michelle Hoffman, editor-in-chief of Pharmaceutical Technology magazine.
Michelle Hoffman
Editor-in-chief
732.346.3014, mhoffman@advanstar.com
Michelle joined Pharmaceutical Technology in 2007. She previously served as editor-in-chief of Drug Discovery & Development, G&P, and BioPerform. She has served as the senior science editor for Harvard Medical School followed by almost a decade as the associate editor (life sciences) for American Scientist magazine. In addition, she was formerly a member of the news staff at Science magazine and an editor at Cell. During her business career, she has been a member of the launch teams of two biotech startups, Quantum Genomics (functional genomics) and Karyogen (drug discovery). Michelle also analyzed new ventures at BD Technologies (part of Becton Dickinson) as a member of the business development group. She was trained in molecular biology at Brown and Harvard and holds an MBA from the University of North Carolina at Chapel Hill, where she specialized in corporate finance and entrepreneurship.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.
